HBV Integration Patterns Reveal Why HBeAg-Negative Hepatitis B Stays Hidden
New research shows integrated HBV DNA — not active viral replication — is the dominant source of surface antigen in HBeAg-negative chronic hepatitis B.
Summary
Chronic hepatitis B (CHB) exists in two main phases distinguished by the hepatitis B e antigen (HBeAg). A new study of 56 treatment-naive patients found that in HBeAg-negative CHB, integrated HBV DNA — rather than the actively replicating circular form — is the primary source of hepatitis B surface antigen (HBsAg). Over 78% of HBeAg-negative patients had integrated DNA making up more than half of total liver HBV DNA, compared to only 4% of HBeAg-positive patients. Strikingly, integrated DNA in HBeAg-negative patients clustered at a specific genomic region, suggesting these cells gain a survival advantage and expand clonally. This helps explain why HBeAg-negative patients can maintain high HBsAg levels despite low viral replication — a key challenge for achieving functional cure of hepatitis B.
Detailed Summary
Chronic hepatitis B (CHB) affects over 250 million people worldwide and remains a leading cause of liver cirrhosis and hepatocellular carcinoma. A central challenge in achieving functional cure is eliminating hepatitis B surface antigen (HBsAg), which can originate from two distinct intrahepatic sources: covalently closed circular DNA (cccDNA), the replication template, and integrated HBV DNA (iDNA) embedded in the host genome. Understanding which source dominates in different disease phases has major implications for treatment strategy.
Researchers from the North American Hepatitis B Research Network analyzed liver tissue from 24 HBeAg-positive and 32 HBeAg-negative treatment-naive CHB patients. Using specialized assays — including heat denaturation with plasmid-safe DNase for cccDNA quantification and next-generation sequencing for iDNA junction mapping — they characterized the relative contributions and genomic distribution of each HBV DNA form.
Key findings were striking. HBeAg-positive patients showed higher cccDNA, serum HBV DNA, HBV RNA, and quantitative HBsAg levels, consistent with active viral replication. In contrast, 78% of HBeAg-negative patients had integrated DNA comprising more than 50% of total intrahepatic HBV DNA, while 96% of HBeAg-positive patients had integrated DNA at 50% or less. Critically, HBsAg staining was present in over 85% of both groups despite dramatically lower cccDNA in HBeAg-negative patients — pointing to iDNA as the dominant HBsAg source in that phase.
The integration site patterns also differed markedly. In HBeAg-negative CHB, 52% of integrations clustered at the DR2-DR1 region of the HBV genome, compared to only 16% in HBeAg-positive patients. This clustering suggests clonal expansion of hepatocytes harboring these specific integrants, likely conferring a selective growth advantage.
These findings have direct implications for functional cure strategies. Antiviral therapies targeting cccDNA may be insufficient to eliminate HBsAg in HBeAg-negative patients, where iDNA drives surface antigen production. Novel approaches targeting integrated DNA or its transcription will likely be necessary. The study is limited by its small sample size and abstract-only availability for this summary.
Key Findings
- 78% of HBeAg-negative CHB patients had integrated HBV DNA exceeding 50% of total liver HBV DNA.
- HBsAg staining was high (>85%) in both groups despite far lower cccDNA in HBeAg-negative patients.
- 52% of integrations in HBeAg-negative CHB clustered at DR2-DR1, suggesting clonal hepatocyte expansion.
- HBeAg-positive CHB showed random integration sites and higher cccDNA, RNA, and serum HBV DNA levels.
- Integrated DNA — not active replication — appears to be the primary HBsAg source in HBeAg-negative CHB.
Methodology
This cross-sectional study analyzed liver biopsies from 56 treatment-naive CHB patients (24 HBeAg-positive, 32 HBeAg-negative) enrolled in the North American Hepatitis B Research Network. cccDNA was quantified using heat denaturation and plasmid-safe ATP-dependent DNase digestion followed by real-time PCR; iDNA was characterized via HBV hybridization-targeted next-generation sequencing to identify HBV-host junction sequences and integration sites.
Study Limitations
The study included only 56 participants, limiting statistical power and generalizability across diverse CHB populations. This summary is based on the abstract only, as the full text is not open access, so methodological details and subgroup analyses may be incompletely represented. Potential conflicts of interest exist, including industry affiliations among several co-authors.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.